This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $350,000 in funding to the University of Washington to support research on the transcriptional outputs of the necroptotic cell death pathway. The research aims to define the specific interactions and transcriptional programs activated by necroptosis pathway components, study the role of necroptosis activation in...
This $453,900 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is funding research to develop a genome editing platform using broadly functioning phage recombinases, which can be used to genetically manipulate a wide range of bacterial species, including clinically relevant pathogens. The goal is to enable direct investigation of the genetic elements driving bacterial...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $565,149 to Health Research, Inc. Wadsworth Center Division to conduct research on RNA-based regulatory mechanisms in Mycobacterium tuberculosis (MTB). The primary objectives are to: Define the regulatory interactions of the sRNA MCR11 and its impact on gene expression in MTB. Characterize the roles of RNA-ABMR...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $785,511 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Chicago. The purpose of this 5-year project, which commenced on January 24, 2025, is to leverage induced pluripotent stem cell-derived macrophages to: Characterize inter-individual and inter-population variability in immune responses to Mycobacterium tuberculosis and influenza virus infections in humans....
This $221,888 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate mechanisms for inducing apoptosis (programmed cell death) in Th17 cells, which play a pathogenic role in many inflammatory and autoimmune diseases. The research aims to explore how simultaneously targeting the IRE1 and STAT3 signaling pathways in Th17 cells can lead to their death,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $192,788 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of California, San Diego (UC San Diego) to identify regulators of plasmacytoid dendritic cell (pDC) function and exhaustion. The research aims to provide the first genome-wide analysis of type I interferon (IFN-I) regulation in pDCs, which are critical for the body's defense against viral infections and cancers. The...
This federal Project Grant award, valued at $800,005.00 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at understanding the structural basis for how genetic variants in G-protein coupled receptors (GPCRs) impact function and contribute to autoimmune diseases. The key objectives of the research project are to: 1) Define the structural basis for impaired function of...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $492,000.00 to The Regents of the University of California, San Francisco (UCSF) to conduct systematic genetic research on the mechanisms governing immunogenic cell death (ICD). The research aims to decipher the signaling pathways and molecular processes that regulate the immune system's ability to recognize...
This $791,864 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding research at the University of California, Riverside (UC Riverside) to decipher the role of non-coding RNAs in gene regulation for the human malaria parasite Plasmodium falciparum. The project aims to elucidate the importance of long non-coding RNAs (lncRNAs) in parasite development, virulence, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the role of the LRRK2-G2019S genetic variant in promoting necroptotic cell death and inflammation in macrophages. The $162,000 award to Tulane University will support research to uncover how this Parkinson's disease-associated variant can reprogram innate immune pathways and cell death modalities,...
This Project Grant award, with a total funding amount of $3,258,391, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to elucidate the regulatory mechanisms by which the RNA splicing factors RAVER1 and PTBP1 control cell death, inflammation, and innate immunity pathways. Specifically, the research aims to determine the roles of RAVER1 and PTBP1 in regulating the RIPK1 signaling pathway, which serves as a critical decision point for multiple cell death and inflammatory processes. The project will include in vitro studies using RAVER1-/- cell lines and in vivo validation using a RAVER1-/- mouse model. Completion of the research will advance the understanding of how central regulators of cell death and inflammation are controlled, enabling the development of targeted strategies to prevent and treat diseases resulting from dysregulation of these pathways.